Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors

Nuclear Medicine and Biology

Volumn 35, Issue 5, 2008, Pages 579-588

  Meier, Reinhard ^a   Piert, Morand ^b   Piontek, Guido ^c   Rudelius, Martina ^c   Oostendorp, Robert A ^c   Senekowitsch Schmidtke, Reingard ^c   Henning, Tobias D ^a   Wels, Winfried S ^d   Uherek, Christoph ^d   Rummeny, Ernst J ^c   Daldrup Link, Heike E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

18F 2 fluoro 2 deoxyl D glucose; Autoradiography; Biodistribution; Cell targeting; Molecular imaging; NK cells

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; RECOMBINANT HUMAN INSULIN; RECOMBINANT INTERLEUKIN 2; ANTIDIABETIC AGENT; CD57 ANTIGEN; DIAGNOSTIC AGENT; ERBB2 PROTEIN, MOUSE; INSULIN; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL LABELING; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DIGITAL RADIOGRAPHY; DNA MODIFICATION; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGING SYSTEM; INTERMETHOD COMPARISON; ISOTOPE LABELING; MOLECULAR IMAGING; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; SCINTILLATION COUNTING; TISSUE DISTRIBUTION; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL STRAIN 3T3; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MONOCYTE; NUDE MOUSE; PROTEIN ENGINEERING; SCINTISCANNING; TUMOR CELL LINE;

3T3 CELLS; ANIMALS; ANTIGENS, CD57; AUTORADIOGRAPHY; CELL LINE, TUMOR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INSULIN; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; MICE, NUDE; MONOCYTES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROTEIN ENGINEERING; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2;

EID: 45549106871     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.02.006     Document Type: Article

References (43)

1. Dewan M.Z., Terunuma H., Takada M., Tanaka Y., Abe H., Sata T., et al. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat 104 3 (2007) 267-275 Epub 2006 Oct 26
2. Stein M.N., Shin J., Gudzowaty O., Bernstein A.M., and Liu J.M. Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. Anticancer Res 26 3A (2006) 1759-1763
3. Tam Y.K., Miyagawa B., Ho V.C., and Klingemann H.G. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 8 3 (1999) 281-290
4. Raulet D.H., Vance R.E., and McMahon C.W. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 19 (2001) 291-330
5. Whiteside T.L. Immune cells in the tumor microenvironment-mechanisms responsible for functional and signaling defects. Gene Therapy of Cancer 451 (1998) 167-171
6. Mulatero C.W., Penson R.T., Papamichael D., Gower N.H., Evans M., and Rudd R.M. A Phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 31 1 (2001) 67-72
7. Maraninchi D., Vey N., Viens P., Stoppa A.M., Archimbaud E., Attal M., et al. A Phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk Lymphoma 31 3-4 (1998) 343-349
8. Tonn T., Becker S., Esser R., Schwabe D., and Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 10 4 (2001) 535-544
9. Yan Y., Steinherz P., Klingemann H.G., Dennig D., Childs B.H., McGuirk J., et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 4 11 (1998) 2859-2868
10. Klingemann H.G., Wong E., and Maki G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant 2 2 (1996) 68-75
11. Uherek C., Tonn T., Uherek B., Becker S., Schnierle B., Klingemann H.G., et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100 4 (2002) 1265-1273
12. Klapper L.N., Kirschbaum M.H., Sela M., and Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77 (2000) 25-79
13. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 13 (2000) 3159-3167
14. Daldrup-Link H.E., Meier R., Rudelius M., Piontek G., Piert M., Metz S., et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol 15 1 (2005) 4-13
15. Fawwaz R.A., Oluwole S., Wang T.S., Kuromoto N., Iga C., Hardy M.A., et al. Biodistribution of radiolabeled lymphocytes. Radiology 155 2 (1985) 483-486
16. Melder R.J., Brownell A.L., Shoup T.M., Brownell G.L., and Jain R.K. Imaging of activated natural killer cells in mice by positron emission tomography: preferential uptake in tumors. Cancer Res 53 24 (1993) 5867-5871
17. 4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci U S A 99 5 (2002) 3030-3035
18. + T-cells to the pancreas in real time. Diabetes 53 6 (2004) 1459-1466
19. Oostendorp R.A., Ghaffari S., and Eaves C.J. Kinetics of in vivo homing and recruitment into cycle of hematopoietic cells are organ-specific but CD44-independent. Bone Marrow Transplant 26 5 (2000) 559-566
20. Daldrup-Link H.E., Rudelius M., Metz S., Piontek G., Pichler B., Settles M., et al. Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur J Nucl Med Mol Imaging 31 9 (2004) 1312-1321
21. Lewin M., Carlesso N., Tung C.H., Tang X.W., Cory D., Scadden D.T., et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18 4 (2000) 410-414
22. Daldrup-Link H.E., Rudelius M., Piontek G., Metz S., Brauer R., Debus G., et al. Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. Radiology 234 1 (2005) 197-205
23. Metz S., Bonaterra G., Rudelius M., Settles M., Rummeny E.J., and Daldrup-Link H.E. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol 14 10 (2004) 1851-1858
24. Schoepf U., Marecos E.M., Melder R.J., Jain R.K., and Weissleder R. Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies. Biotechniques 24 4 (1998) 642-651
25. Smirnov P., Gazeau F., Lewin M., Bacri J.C., Siauve N., Vayssettes C., et al. In vivo cellular imaging of magnetically labeled hybridomas in the spleen with a 1.5-T clinical MRI system. Magn Reson Med 52 1 (2004) 73-79
26. Weissleder R., Cheng H.C., Bogdanova A., and Bogdanov Jr. A. Magnetically labeled cells can be detected by MR imaging. J Magn Reson Imaging 7 1 (1997) 258-263
27. Yeh T.C., Zhang W., Ildstad S.T., and Ho C. In vivo dynamic MRI tracking of rat T-cells labeled with superparamagnetic iron-oxide particles. Magn Reson Med 33 2 (1995) 200-208
28. Melder R.J., Elmaleh D., Brownell A.L., Brownell G.L., and Jain R.K. A method for labeling cells for positron emission tomography (PET) studies. J Immunol Methods 175 1 (1994) 79-87
29. 18F-FDG labelling of human leukocytes. Nucl Med Commun 21 7 (2000) 691-694
30. 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J Nucl Med 47 8 (2006) 1295-1301
31. 18F-FDG. J Nucl Med 46 9 (2005) 1522-1530
32. 111In-oxine-labeled leukocytes for detection of infection. Radiology 238 3 (2006) 978-987
33. Ritchie D., Mileshkin L., Wall D., Bartholeyns J., Thompson M., Coverdale J., et al. In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunol Immunother 56 2 (2007) 155-163
34. 18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27 2 (1986) 235-238
35. 18F]fluorodeoxyglucose labelling and retention for in vivo positron emission tomography imaging of monocyte trafficking. Nucl Med Commun 23 6 (2002) 551-557
36. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 3 (2002) 719-726
37. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
38. Uherek C., Groner B., and Wels W. Chimeric antigen receptors for the retargeting of cytotoxic effector cells. J Hematother Stem Cell Res 10 4 (2001) 523-534
39. Bai J., Ding W., Yu M., Du J., Liu Z., Jia B., et al. Radionuclide imaging of mesenchymal stem cells transplanted into spinal cord. Neuroreport 15 7 (2004) 1117-1120
40. Barbash I.M., Chouraqui P., Baron J., Feinberg M.S., Etzion S., Tessone A., et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108 7 (2003) 863-868
41. 111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nucl Med Commun 24 11 (2003) 1149-1154
42. Gao J., Dennis J.E., Muzic R.F., Lundberg M., and Caplan A.I. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169 1 (2001) 12-20
43. 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm 19 2 (2004) 155-163